This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Evaluation of Viridian Therapeutics’ Elegrobart and Amgen TEPEZZA® (teprotumumab)
Ticker(s): VRDN, AMGNWho's the expert?
Institution: California Oculoplastics
- Sees 2-3 patients with TED per week and manages at least 50.
- Involved in multiple TED trials in his career including: ASCEND GO-2: Study of batoclimab (RVT-1401), Phase 2/3 clinical trials for Tepezza, and work on IGF-1R pathways.
- Author of paper: Enrichment of IGF-1R and PPAR Signaling Pathways in Orbital Inflammatory Diseases: Steps Toward Understanding Pathogenesis.
Interview GoalThis conversation will focus on the landscape of Thyroid Eye Disease along with the potential of Viridian Therapeutics' Elegrobart VRDN-003 and Amgen TEPEZZA® (teprotumumab)
Are You Interested In These Questions?
Slingshot Insights Explained
- Call Date
- Apr 27, 2026
- Call Time
- 03:15 PM EDT
Wall Street Time
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
